Active Ingredient History
Isavuconazole is an active form of isavuconazonium, a prodrug which is marketed under the name Cresemba. Isavuconazole inhibits lanosterol 14-alpha demethylase (or CYP51A1) and leads to the accumulation of ergosterol toxic precursors in the fungal cytoplasm. Isavuconazole is indicated for the treatment of invasive aspergillosis and invasive mucormycosis. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Aspergillosis (Phase 3)
Candidemia (Phase 3)
Candidiasis, Invasive (Phase 3)
Healthy Volunteers (Phase 1)
Hematologic Neoplasms (Phase 2)
Immunocompromised Host (Phase 3)
Invasive Fungal Infections (Phase 3)
Invasive Pulmonary Aspergillosis (Phase 2)
Kidney Diseases (Phase 1)
Leukemia, Myeloid, Acute (Phase 2/Phase 3)
Lung Diseases (Phase 3)
Lymphoma (Phase 2)
Mycoses (Phase 4)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Neutropenia (Phase 2)
Pharmacokinetics (Phase 1)
SARS-CoV-2 (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue